Issue 23, 2006
From the journal:

Chemical Communications

In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin†‡

Dirk V. Deubel*a  and  Justin Kai-Chi Laua  

* Corresponding authors

a ETH Zurich, USI Campus, Computational Science, Via Guiseppe Buffi 13, Lugano, Switzerland
E-mail: metals-in-medicine@phys.chem.ethz.ch

Abstract

A comparative quantum chemical approach helps to clarify how the selectivity of anticancer metallopharmaceuticals towards potential biological targets can be controlled by metal and ligands.

Graphical abstract: In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/B601590E
Article type
Communication
Submitted
03 Feb 2006
Accepted
20 Apr 2006
First published
05 May 2006

Chem. Commun., 2006, 2451-2453

Permissions

Request permissions

In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin

D. V. Deubel and J. K. Lau, Chem. Commun., 2006, 2451 DOI: 10.1039/B601590E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements